LEXICON ANNOUNCES FDA APPROVAL OF INPEFA™ (SOTAGLIFLOZIN) FOR TREATMENT OF HEART FAILURE

Date postedMay 26, 2023

The Woodlands, Texas, May 26, 2023 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has approved INPEFA™ (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:

  • heart failure or
  • type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.


Read more…

Categories

Community Industry

Most Recent Posts

Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials Date postedMay 2, 2024Posted Medicare plans can now cover Wegovy for patients at risk of heart disease Date postedMarch 22, 2024Posted U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiova Date postedMarch 22, 2024Posted PRALUENT® (ALIROCUMAB) INJECTION RECEIVES FDA APPROVAL TO TREAT CHILDREN WITH GENETIC FORM OF HIGH C Date postedMarch 11, 2024Posted Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease a Date postedMarch 8, 2024Posted